{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:34:37Z","timestamp":1790854477167,"version":"4.1.0"},"reference-count":145,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["BT\/PR40394\/COV\/140\/1\/2020"],"award-info":[{"award-number":["BT\/PR40394\/COV\/140\/1\/2020"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017204","name":"Instituto de Tecnolog\u00eda Qu\u00edmica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017204","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.drudis.2021.07.021","type":"journal-article","created":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T02:53:30Z","timestamp":1627527210000},"page":"2619-2636","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":207,"title":["Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management"],"prefix":"10.1016","volume":"26","author":[{"given":"Vivek P.","family":"Chavda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalitkumar K.","family":"Vora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali K.","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana B.","family":"Patravale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.drudis.2021.07.021_b0005","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: from basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.drudis.2021.07.021_b0010","unstructured":"Bloomberg. Vaccine Tracker. www.bloomberg.com\/graphics\/covid-vaccine-tracker-global-distribution\/ [accessed August 6, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0015","unstructured":"Zimmer C, Corum J, Wee S-L. Coronavirus vaccine tracker. NYTimes. www.nytimes.com\/interactive\/2020\/science\/coronavirus-vaccine-tracker.html [accessed August 6, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0020","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.addr.2021.01.002","article-title":"Nanocarrier vaccines for SARS-CoV-2","volume":"171","author":"Machhi","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.drudis.2021.07.021_b0025","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s13577-021-00512-4","article-title":"COVID-19 vaccines: rapid development, implications, challenges and future prospects","volume":"34","author":"Kashte","year":"2021","journal-title":"Hum Cell"},{"issue":"7830","key":"10.1016\/j.drudis.2021.07.021_b0030","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.drudis.2021.07.021_b0035","first-page":"729","article-title":"Advantages of intranasal vaccination and considerations on device selection","volume":"71","author":"Birkhoff","year":"2009","journal-title":"Indian J Pharm Sci"},{"issue":"2","key":"10.1016\/j.drudis.2021.07.021_b0040","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3390\/v13020317","article-title":"Viral vectors for COVID-19 vaccine development","volume":"13","author":"Lundstrom","year":"2021","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.drudis.2021.07.021_b0045","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41392-021-00527-1","article-title":"COVID-19 in early 2021: current status and looking forward","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduction Targeted Therapy"},{"issue":"8","key":"10.1016\/j.drudis.2021.07.021_b0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008762","article-title":"COVID-19 pandemic: insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2","volume":"16","author":"Mittal","year":"2020","journal-title":"PLoS Pathogens"},{"key":"10.1016\/j.drudis.2021.07.021_b0055","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.drudis.2021.07.021_b0060","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/jmv.25762","article-title":"The establishment of reference sequence for SARSCoV-2 and variation analysis","volume":"92","author":"Wang","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.drudis.2021.07.021_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173548","article-title":"COVID-19 associated complications and potential therapeutic targets","volume":"886","author":"Monpara","year":"2020","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"10.1016\/j.drudis.2021.07.021_b0070","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cell.2020.05.034","article-title":"Structural basis for RNA replication by the SARS-CoV-2 polymerase","volume":"182","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2021.07.021_bib717","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s11481-020-09981-0","article-title":"A Role for Extracellular Vesicles in SARS-CoV-2 Therapeutics and Prevention","volume":"16","author":"Machhi","year":"2021","journal-title":"Journal of Neuroimmune Pharmacology"},{"key":"10.1016\/j.drudis.2021.07.021_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102433","article-title":"The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak","volume":"109","author":"Rothan","year":"2020","journal-title":"J Autoimmun"},{"key":"10.1016\/j.drudis.2021.07.021_b0080","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.drudis.2021.07.021_b0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076469","article-title":"Role of the Spike glycoprotein of human Middle East respiratory syndrome coronavirus (MERS-CoV) in virus entry and syncytia formation","volume":"8","author":"Qian","year":"2013","journal-title":"PLoS ONE"},{"issue":"17","key":"10.1016\/j.drudis.2021.07.021_b0090","doi-asserted-by":"crossref","first-page":"8887","DOI":"10.1128\/JVI.00415-08","article-title":"Cathepsin L Functionally cleaves the severe acute respiratory syndrome coronavirus Class I fusion protein upstream of rather than adjacent to the fusion peptide","volume":"82","author":"Bosch","year":"2008","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.drudis.2021.07.021_b0095","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.bbrc.2004.09.106","article-title":"Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: Implication for developing subunit vaccine","volume":"324","author":"He","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2021.07.021_b0100","first-page":"1","article-title":"Host factors in coronavirus replication","volume":"419","author":"de Wilde","year":"2018","journal-title":"Curr Top Microbiol Immunol"},{"issue":"4","key":"10.1016\/j.drudis.2021.07.021_b0105","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/diseases4030026","article-title":"Human coronaviruses: a review of virus\u2013host interactions","volume":"4","author":"Lim","year":"2016","journal-title":"Diseases"},{"key":"10.1016\/j.drudis.2021.07.021_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-2438-7_1","article-title":"an overview of their replication and pathogenesis","volume":"1282","author":"Fehr","year":"2015","journal-title":"Coronaviruses: Methods Protocols"},{"key":"10.1016\/j.drudis.2021.07.021_b0115","first-page":"533","article-title":"Functional exhaustion of antiviral lymphocytes in COVID-19 patients","volume":"17","author":"Zheng","year":"2020","journal-title":"CellMol Immunol"},{"key":"10.1016\/j.drudis.2021.07.021_b0120","doi-asserted-by":"crossref","first-page":"E220","DOI":"10.3390\/vaccines8020220","article-title":"A novel synonymous mutation of SARS-CoV-2: is this possible to affect their antigenicity and immunogenicity?","volume":"8","author":"Kim","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.drudis.2021.07.021_b0125","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1126\/science.abb8925","article-title":"Cytokine release syndrome in severe COVID-19","volume":"368","author":"Moore","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.drudis.2021.07.021_b0130","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41577-020-0346-x","article-title":"Dysregulation of type I interferon responses in COVID-19","volume":"20","author":"Acharya","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.drudis.2021.07.021_b0135","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41392-020-00243-2","article-title":"COVID-19: immunopathogenesis and immunotherapeutics","volume":"5","author":"Yang","year":"2020","journal-title":"Signal Transduction Targeted Therapy"},{"key":"10.1016\/j.drudis.2021.07.021_b0140","unstructured":"Verardi P. How worried should you be about coronavirus variants? A virologist explains his concerns. www.downtoearth.org.in\/blog\/health\/how-worried-should-you-be-about-coronavirus-variants-a-virologist-explains-his-concerns-76384 [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0145","unstructured":"Bentley M. Known unknowns: Covid-19 and biological warfare. E-International Relations. www.e-ir.info\/2020\/08\/08\/known-unknowns-covid-19-and-biological-warfare\/ [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0150","unstructured":"CDC. Cases, data, and surveillance. www.cdc.gov\/coronavirus\/2019-ncov\/cases-updates\/variant-surveillance\/variant-info.html [accessed July 2, 2021]."},{"issue":"2","key":"10.1016\/j.drudis.2021.07.021_b0155","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/0194599820982633","article-title":"COVID-19 vaccines may not prevent nasal SARS-CoV-2 infection and asymptomatic transmission","volume":"164","author":"Bleier","year":"2021","journal-title":"Otolaryngol Head Neck Surgery"},{"issue":"1","key":"10.1016\/j.drudis.2021.07.021_b0160","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/jan.13818","article-title":"The fear of needles: a systematic review and meta-analysis","volume":"75","author":"McLenon","year":"2019","journal-title":"J Adv Nurs"},{"issue":"3","key":"10.1016\/j.drudis.2021.07.021_b0165","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1086\/505580","article-title":"Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the Group A streptococcal M protein","volume":"194","author":"Olive","year":"2006","journal-title":"J Infect Dis"},{"issue":"577","key":"10.1016\/j.drudis.2021.07.021_b0170","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd2223","article-title":"IgA dominates the early neutralizing antibody response to SARS-CoV-2","volume":"13","author":"Sterlin","year":"2021","journal-title":"Sci Transl Med"},{"issue":"8","key":"10.1016\/j.drudis.2021.07.021_b0175","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.addr.2007.05.017","article-title":"Nanotechnology in vaccine delivery","volume":"60","author":"Peek","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.drudis.2021.07.021_b0180","article-title":"Features and functions of systemic and mucosal humoral immunity among SARS-CoV-2 convalescent individuals","author":"Butler","year":"2020","journal-title":"medRxiv"},{"issue":"1","key":"10.1016\/j.drudis.2021.07.021_b0185","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/21645515.2016.1239668","article-title":"Current prospects and future challenges for nasal vaccine delivery","volume":"13","author":"Yusuf","year":"2017","journal-title":"Human Vacc Immunotherap"},{"issue":"9","key":"10.1016\/j.drudis.2021.07.021_b0190","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/nri2832","article-title":"New insights into the development of lymphoid tissues","volume":"10","author":"van de Pavert","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.drudis.2021.07.021_b0195","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1172\/JCI119522","article-title":"Epithelial cells as sensors for microbial infection","volume":"100","author":"Kagnoff","year":"1997","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.drudis.2021.07.021_b0200","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10875-005-8065-4","article-title":"Innate sensors of microbial infection","volume":"25","author":"Hargreaves","year":"2005","journal-title":"J Clin Immunol"},{"issue":"9","key":"10.1016\/j.drudis.2021.07.021_b0205","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nri1439","article-title":"NALT- versus Peyer\u2019s-patch-mediated mucosal immunity","volume":"4","author":"Kiyono","year":"2004","journal-title":"Nat Rev Immunol"},{"issue":"4\u20135","key":"10.1016\/j.drudis.2021.07.021_b0210","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3109\/08820131003680369","article-title":"Function of mucosa-associated lymphoid tissue in antibody formation","volume":"39","author":"Brandtzaeg","year":"2010","journal-title":"Immunol Invest"},{"issue":"3","key":"10.1016\/j.drudis.2021.07.021_b0215","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/jps.20718","article-title":"Nanoparticulate systems for nasal delivery of drugs: a real improvement over simple systems?","volume":"96","author":"Illum","year":"2007","journal-title":"J Pharm Sci"},{"issue":"5824","key":"10.1016\/j.drudis.2021.07.021_b0220","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1126\/science.1137971","article-title":"Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation","volume":"316","author":"Burgdorf","year":"2007","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.drudis.2021.07.021_b0225","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.immuni.2007.02.004","article-title":"Debugging how bacteria manipulate the immune response","volume":"26","author":"Sansonetti","year":"2007","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.drudis.2021.07.021_b0230","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/17425247.2020.1731468","article-title":"Non-invasive mucosal vaccine delivery: advantages, challenges and the future","volume":"17","author":"Skwarczynski","year":"2020","journal-title":"Expert Opin Drug Deliv"},{"issue":"8","key":"10.1016\/j.drudis.2021.07.021_b0235","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nri3251","article-title":"Recent progress in mucosal vaccine development: potential and limitations","volume":"12","author":"Lycke","year":"2012","journal-title":"Nat Rev Immunol"},{"issue":"34","key":"10.1016\/j.drudis.2021.07.021_b0240","doi-asserted-by":"crossref","first-page":"13823","DOI":"10.1073\/pnas.1208075109","article-title":"Protection from the acquisition of Staphylococcus aureus nasal carriage by cross-reactive antibody to a pneumococcal dehydrogenase","volume":"109","author":"Lijek","year":"2012","journal-title":"PNAS"},{"issue":"4 Suppl","key":"10.1016\/j.drudis.2021.07.021_b0245","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1038\/nm1210","article-title":"Targeting the innate immune response with improved vaccine adjuvants","volume":"11","author":"Pashine","year":"2005","journal-title":"Nat Med"},{"issue":"41","key":"10.1016\/j.drudis.2021.07.021_b0250","doi-asserted-by":"crossref","first-page":"12782","DOI":"10.1073\/pnas.1513532112","article-title":"Generation of Th17 cells in response to intranasal infection requires TGF-\u03b21 from dendritic cells and IL-6 from CD301b+ dendritic cells","volume":"112","author":"Linehan","year":"2015","journal-title":"PNAS"},{"issue":"7","key":"10.1016\/j.drudis.2021.07.021_b0255","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s13238-015-0164-2","article-title":"Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies","volume":"6","author":"Wang","year":"2015","journal-title":"Protein & Cell"},{"issue":"10","key":"10.1016\/j.drudis.2021.07.021_b0260","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3109\/1061186X.2010.523790","article-title":"Nasal vaccine innovation","volume":"18","author":"Jabbal-Gill","year":"2010","journal-title":"J Drug Target"},{"key":"10.1016\/j.drudis.2021.07.021_bib716","article-title":"Self-assembled nanocomplexes of anionic pullulan and polyallylamine for DNA and pH-sensitive intracellular drug delivery","volume":"16","author":"Vora","year":"2014","journal-title":"Journal of Nanoparticle Research volume"},{"issue":"3","key":"10.1016\/j.drudis.2021.07.021_b0265","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4149\/av_2017_301","article-title":"Viral vaccine stabilizers: status and trends","volume":"61","author":"Cardoso","year":"2017","journal-title":"Acta Virol"},{"key":"10.1016\/j.drudis.2021.07.021_b0270","first-page":"e1459394","article-title":"Adjuvants: classification, modus operandi, and licensing","author":"Apost\u00f3lico","year":"2016","journal-title":"J Immunol Res"},{"key":"10.1016\/j.drudis.2021.07.021_b0275","unstructured":"CDC. Adjuvants and Vaccines | Vaccine Safety. www.cdc.gov\/vaccinesafety\/concerns\/adjuvants.html (accessed July 2, 2021)."},{"key":"10.1016\/j.drudis.2021.07.021_b0280","unstructured":"CDC. Live attenuated influenza vaccine (the nasal spray flu vaccine). www.cdc.gov\/flu\/prevent\/nasalspray.html (accessed July 2, 2021)."},{"issue":"44","key":"10.1016\/j.drudis.2021.07.021_b0285","doi-asserted-by":"crossref","first-page":"6629","DOI":"10.1016\/j.vaccine.2006.05.035","article-title":"The virosomal influenza vaccine Invivac\u00ae: Immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad\u00ae) in elderly subjects","volume":"24","author":"de Bruijn","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.drudis.2021.07.021_b0290","doi-asserted-by":"crossref","unstructured":"Heida R, Hinrichs WL, Frijlink HW. Inhaled vaccine delivery in the combat against respiratory viruses: a 2021 overview of recent developments and implications for COVID-19. Expert Rev Vacc [published online March 22, 2021]. http:\/\/dx.doi.org\/10.1080\/14760584.2021.1903878.","DOI":"10.1080\/14760584.2021.1903878"},{"key":"10.1016\/j.drudis.2021.07.021_b0295","unstructured":"WHO. The different types of COVID-19 vaccines. www.who.int\/news-room\/feature-stories\/detail\/the-race-for-a-covid-19-vaccine-explained. [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0300","unstructured":"FluMist \u2013 FDA prescribing information, side effects and uses. www.drugs.com\/pro\/flumist.html [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0305","unstructured":"Balfour H. First patient dosed with intranasal COVID-19 vaccine candidate. European Pharmaceutical Review. www.europeanpharmaceuticalreview.com\/news\/139089\/first-patient-dosed-with-covi-vac-an-intranasal-covid-19-vaccine-candidate\/ [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0310","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.589833","article-title":"Adjuvants for coronavirus vaccines","volume":"11","author":"Liang","year":"2020","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.drudis.2021.07.021_b0315","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/j.ymthe.2020.10.002","article-title":"Pros and cons of adenovirus-based SARS-CoV-2 vaccines","volume":"28","author":"Kremer","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.drudis.2021.07.021_b0320","unstructured":"Janssen. Vaccine technology. www.janssen.com\/infectious-diseases-and-vaccines\/vaccine-technology [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0325","unstructured":"CDC. Janssen COVID-19 Vaccine (Johnson & Johnson): Vaccine preparation and administration summary. www.cdc.gov\/vaccines\/covid-19\/info-by-product\/janssen\/downloads\/Janssen-Prep-and-Admin-Summary.pd. [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0330","unstructured":"Vaccine Knowledge Project. COVID-19 vaccines. https:\/\/vk.ovg.ox.ac.uk\/vk\/covid-19-vaccines [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0335","unstructured":"Precision Vaccinations. Sputnik V Vaccine. www.precisionvaccinations.com\/vaccines\/sputnik-v-vaccine [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0340","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3389\/fmicb.2020.00298","article-title":"Subunit vaccines against emerging pathogenic human coronaviruses","volume":"11","author":"Wang","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.drudis.2021.07.021_b0345","unstructured":"FDA. Moderna COVID-19 vaccine. www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/moderna-covid-19-vaccine [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0350","unstructured":"WHO. WHO recommendation Tozinameran \u2013 COVID-19 mRNA vaccine (nucleoside modified) \u2013 COMIRNATY\u00ae. https:\/\/extranet.who.int\/pqweb\/vaccines\/who-recommendation-covid-19-mrna-vaccine-nucleoside-modified-comirnaty [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0355","unstructured":"Chalmers. Nasal spray could deliver vaccine against COVID-19. www.chalmers.se\/en\/departments\/physics\/news\/Pages\/Nasal_spray_could_deliver_a_future_mRNA_vaccine_against_COVID_19.aspx [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0360","doi-asserted-by":"crossref","first-page":"16030","DOI":"10.1038\/mtm.2016.30","article-title":"Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens","volume":"3","author":"Afkhami","year":"2016","journal-title":"Mol Therapy Methods Clin Develop"},{"issue":"2","key":"10.1016\/j.drudis.2021.07.021_b0365","doi-asserted-by":"crossref","first-page":"97","DOI":"10.7774\/cevr.2013.2.2.97","article-title":"Viral vectors for vaccine applications","volume":"2","author":"Choi","year":"2013","journal-title":"Clin Exp Vaccine Res"},{"key":"10.1016\/j.drudis.2021.07.021_b0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111254","article-title":"Targets and strategies for vaccine development against SARS-CoV-2","volume":"137","author":"Malik","year":"2021","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"10.1016\/j.drudis.2021.07.021_b0375","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1080\/21645515.2017.1419108","article-title":"Development of novel vaccine vectors: chimpanzee adenoviral vectors","volume":"14","author":"Guo","year":"2018","journal-title":"Human Vacc Immunotherap"},{"key":"10.1016\/j.drudis.2021.07.021_b0380","unstructured":"University of Oxford. University of Oxford to study nasal administration of COVID-19 vaccine. www.ox.ac.uk\/news\/2021-03-25-university-oxford-study-nasal-administration-covid-19-vaccine [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0385","article-title":"Intranasal ChAdOx1 nCoV-19\/AZD1222 vaccination reduces shedding of SARS-CoV-2 D614G in rhesus macaques","author":"Van Doremalen","year":"2021","journal-title":"IoRxiv"},{"issue":"1","key":"10.1016\/j.drudis.2021.07.021_b0390","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cell.2020.08.026","article-title":"A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2","volume":"183","author":"Hassan","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2021.07.021_b0395","unstructured":"Bharat Biotech. Intranasal vaccine For Covid-19. www.bharatbiotech.com\/intranasal-vaccine.html [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0400","unstructured":"St. Louis-based Precision Virologics and India\u2019s Biotech leader Bharat Biotech obtain rights to intranasal COVID-19 vaccine technology. www.biostl.org\/news-and-media\/home\/st-louis-based-precision-virologics-and-indias-biotech-leader-bharat-biotech-obtain-rights-to-intranasal-covid-19-vaccine-technology [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0405","unstructured":"CanSino Biologics Inc. A randomized, double-blind, placebo-controlled Phase I\/II clinical trial to evaluate the safety and immunogenicity of Ad5-NCoV for inhalation in adults 18 years of age and older. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04840992 [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0410","unstructured":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. A Phase III randomized, double-blind, placebo-controlled clinical trial in 18 years of age and above to determine the safety and efficacy of ZF2001, a recombinant novel coronavirus vaccine (CHO Cell) for prevention of COVID-19. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04646590 [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0415","unstructured":"Altimmune, Inc. Phase 2, double-blind, randomized, placebo-controlled study of NasoVAX in the prevention of clinical worsening in patients with early Coronavirus infectious disease 2019 (COVID-19). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04442230 [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0420","article-title":"Single-dose intranasal administration of AdCOVID elicits systemic and mucosal immunity against SARS-CoV-2 in mice","author":"King","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.drudis.2021.07.021_b0425","unstructured":"NasoVAX Influenza Vaccine. www.precisionvaccinations.com\/vaccines\/nasovax-influenza\u2013vaccine [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0430","unstructured":"FluGen Inc. Focused on efficacy \u2013 M2SR: the vaccine. http:\/\/flugen.com\/m2sr\/ [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0435","unstructured":"Clinical Research and Development Company \u2013 Bharat Biotech. www.bharatbiotech.com\/r&d_pipeline.html [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0440","first-page":"2","article-title":"M2SR, a single replication universal flu vaccine","volume":"4","author":"Bilsel","year":"2015","journal-title":"Virol-Mycol"},{"key":"10.1016\/j.drudis.2021.07.021_b0445","unstructured":"The University of Hong Kong. A Phase 1, randomized, double-blinded, placebo-controlled, dose-escalation and dose-expansion study to evaluate the safety and immunogenicity of DelNS1-NCoV-RBD LAIV for COVID-19 in Healthy Adults. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04809389 [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0450","unstructured":"Clinical Trials Arena. Nasal spray vaccine for Covid-19. www.clinicaltrialsarena.com\/comment\/nasal-spray-vaccine-covid-19\/ [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0455","unstructured":"The Scientist Magazine. Track COVID-19 vaccines advancing through clinical trials. www.the-scientist.com\/news-opinion\/track-covid-19-vaccines-advancing-through-clinical-trials-67382 [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0460","unstructured":"Meissa Vaccines, Inc. Phase 1, open-label, dose-escalation study to evaluate tolerability, safety, and immunogenicity of an intranasal live attenuated respiratory syncytial virus vaccine expressing Spike protein of SARS-CoV-2 in healthy adults ages 18\u201369 Years. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04798001 [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0465","unstructured":"Illinois Institute of Technology. Promising new COVID-19 treatment in development at Illinois Tech. www.iit.edu\/news\/promising-new-covid-19-treatment-development-illinois-tech. [Accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0470","unstructured":"Intravacc. Intravacc announces positive pre-clinical data for its SARS-CoV-2 nose spray vaccine. www.intravacc.nl\/news\/intravacc-announces-positive-pre-clinical-data-intranasal-sars-cov-2-candidate-vaccine\/ [accessed July 2, 2021]."},{"issue":"1\u20132","key":"10.1016\/j.drudis.2021.07.021_b0475","doi-asserted-by":"crossref","first-page":"1600013","DOI":"10.1002\/adbi.201600013","article-title":"Liposomal delivery enhances immune activation by STING agonists for cancer immunotherapy","volume":"1","author":"Koshy","year":"2017","journal-title":"Adv Biosyst"},{"key":"10.1016\/j.drudis.2021.07.021_b0480","unstructured":"AuraVax Therapeutics licences intranasal vaccine adjuvant technology from Massachusetts General Hospital. www.oindpnews.com\/2021\/01\/auravax-therapeutics-licences-intranasal-vaccine-adjuvant-technology-from-massachusetts-general-hospital\/ [accessed July 2, 2021]."},{"issue":"4","key":"10.1016\/j.drudis.2021.07.021_b0485","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1089\/jamp.2020.1622","volume":"33","author":"Mitchell","year":"2020","journal-title":"J Aerosol Med Pulmonary Drug Deliv"},{"key":"10.1016\/j.drudis.2021.07.021_b0490","unstructured":"Parkins K. SaNOtize\u2019s \u2018revolutionary\u2019 Covid-19 nasal spray bolstered by Phase II trial data. www.clinicaltrialsarena.com\/news\/sanotize-nasal-spray-reduces-covid-19-viral-load-uk-clinical-trail\/ [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0495","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.niox.2013.03.007","article-title":"Gaseous nitric oxide reduces influenza infectivity in vitro","volume":"31","author":"Regev-Shoshani","year":"2013","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.drudis.2021.07.021_b0500","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.prevetmed.2015.04.008","article-title":"Non-inferiority of nitric oxide releasing intranasal spray compared to sub-therapeutic antibiotics to reduce incidence of undifferentiated fever and bovine respiratory disease complex in low to moderate risk beef cattle arriving at a commercial feedlot","volume":"138","author":"Regev-Shoshani","year":"2017","journal-title":"Preventive Veterinary Med"},{"issue":"4","key":"10.1016\/j.drudis.2021.07.021_b0505","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jcf.2012.01.003","article-title":"A phase I clinical study of inhaled nitric oxide in healthy adults","volume":"11","author":"Miller","year":"2012","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.drudis.2021.07.021_b0510","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/toxsci\/59.1.5","article-title":"The toxicology of inhaled nitric oxide","volume":"59","author":"Weinberger","year":"2001","journal-title":"Toxicol Sci"},{"issue":"1","key":"10.1016\/j.drudis.2021.07.021_b0515","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2009.09.007","article-title":"Dual effect of nitric oxide on SARS-CoV replication: viral RNA production and palmitoylation of the S protein are affected","volume":"395","author":"Akerstr\u00f6m","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.drudis.2021.07.021_b0520","unstructured":"Business Wire. UK clinical trial confirms SaNOtize\u2019s breakthrough treatment for COVID-19. www.businesswire.com\/news\/home\/20210315005197\/en\/UK-Clinical-Trial-Confirms-SaNOtize\u2019s-Breakthrough-Treatment-for-COVID-19 [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0525","unstructured":"SaNOtize Research and Development Corp. Nitric oxide releasing solutions to prevent and treat mild\/moderate COVID-19 infection (NOCOVID). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04337918 [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0530","unstructured":"Beyond Air. Revolutionizing nitric oxide therapy. www.beyondair.net\/ [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0535","unstructured":"VERO Biotech. Technology. www.vero-biotech.com\/technology\/. Published 2020 [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0540","doi-asserted-by":"crossref","unstructured":"Shmuel K, Dalia M, Tair L, Yaakov N. Low pH Hypromellose (Taffix) nasal powder spray could reduce SARS-CoV-2 infection rate post mass-gathering event at a highly endemic community: an observational prospective open label user survey. Expert Rev Anti-infective Therapy Published online April 24, 2021. http:\/\/dx.doi.org\/10.1080\/14787210.2021.1908127.","DOI":"10.21203\/rs.3.rs-100328\/v3"},{"issue":"2","key":"10.1016\/j.drudis.2021.07.021_b0545","first-page":"73","article-title":"Effects of creating a non-specific, virus-hostile environment in the nasopharynx on symptoms and duration of common cold","volume":"27","author":"Hull","year":"2007","journal-title":"Acta Otorhinolaryngol Italica"},{"key":"10.1016\/j.drudis.2021.07.021_b0550","unstructured":"Healthcare Technologies Institute. Anti-COVID-19 nasal spray \u2018ready for use in humans\u2019. www.birmingham.ac.uk\/news\/latest\/2020\/11\/anti-covid-19-nasal-spray-ready-for-use-in-humans.aspx [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0555","article-title":"Formulation of a composite nasal spray enabling enhanced surface coverage and prophylaxis of SARS-COV-2","author":"Moakes","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.drudis.2021.07.021_b0560","unstructured":"Buller F. Neurimmune and Ethris sign collaboration agreement to rapidly develop inhaled mRNA-based antibody therapy for the treatment of Covid-19. Neurimmune AG. www.neurimmune.com\/news\/neurimmune-and-ethris-sign-collaboration-agreement-to-rapidly-develop-inhaled-mrna-based-antibody-therapy-for-the-treatment-of-covid-19 [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0565","unstructured":"Chakraverty A. Swiss and German team to develop inhaled mRNA coronavirus treatment. labiotech. www.labiotech.eu\/trends-news\/ethris-neurimmune-mrna-coronavirus\/ [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0570","unstructured":"Prieschl-Grassauer E. Nasal spray works against COVID-19 variants. www.thepharmaletter.com\/article\/nasal-spray-works-against-covid-19-variants [accessed July 2, 2021]."},{"issue":"6","key":"10.1016\/j.drudis.2021.07.021_b0575","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1176\/appi.ajp.2014.12101342","article-title":"Effect of an acute intranasal aerosol dose of PH94B on social and performance anxiety in women with social anxiety disorder","volume":"171","author":"Liebowitz","year":"2014","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.drudis.2021.07.021_b0580","unstructured":"Zehr L. VistaGen readies Phase 3 trial of novel, fast-acting neuroactive nasal spray in social anxiety disorder. https:\/\/biotuesdays.com\/2021\/02\/09\/vistagen-readies-phase-3-trial-of-novel-fast-acting-neuroactive-nasal-spray-in-social-anxiety-disorder\/ [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0585","unstructured":"VistaGen Therapeutics Inc. PH94B in the treatment of adjustment disorder with anxiety. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04404192 [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0590","unstructured":"SaNOtize. NORSTMas an upper airway \u2018disinfectant.\u2019 https:\/\/sanotize.com\/covid-19\/ [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0595","unstructured":"APEPTICO Forschung und Entwicklung GmbH. APEPTICO\u2019s global survey on incidence of ARDS and outcomes in hospitalized patients with COVID-19 has been published by Critical Care. www.apeptico.com\/index-news [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0600","unstructured":"ClinicalTrials.gov. NCT02074059. Trial to assess the safety and tolerability of lucinactant for inhalation in premature neonates. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02074059 [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0605","unstructured":"ClinicalTrials.gov. NCT04330586. A Trial of ciclesonide in adults with mild-to-moderate COVID-19. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04330586 [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0610","unstructured":"NeuroRx IRTHA. FDA grants inhaled use IND for RLF-100 (aviptadil) to treat patients with moderate and severe COVID-19 aiming to prevent progression to respiratory failure. www.prnewswire.com\/news-releases\/fda-grants-inhaled-use-ind-for-rlf-100-aviptadil-to-treat-patients-with-moderate-and-severe-covid-19-aiming-to-prevent-progression-to-respiratory-failure-301107288.html [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0615","unstructured":"Partner Therapeutics. Partner Therapeutics initiates patient enrollment in U.S. clinical trial evaluating Leukine\u00ae (rhuGM-CSF, sargramostim) in COVID-19 patients. www.partnertx.com\/partner-therapeutics-initiates-patient-enrollment-in-u-s-clinical-trial-evaluating-leukine-rhugm-csf-sargramostim-in-covid-19-patients\/ [accessed July 2, 2021]."},{"issue":"45","key":"10.1016\/j.drudis.2021.07.021_b0620","doi-asserted-by":"crossref","first-page":"26943","DOI":"10.1074\/jbc.M115.682138","article-title":"Novel insights into interleukin 6 (IL-6) cis- and trans-signaling pathways by differentially manipulating the assembly of the IL-6 signaling complex","volume":"290","author":"Lacroix","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2021.07.021_b0625","unstructured":"ClinicalTrials.gov. NCT04456452. Study of Ampion for the treatment of Adult COVID-19 patients requiring oxygen supplementation. ClinicalTrials.gov. NCT04456452. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04456452 [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0630","unstructured":"EudraCT: 2020-001023-14. A randomized double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFN\u03b2-1a for nebulization) for the treatment of patients with confirmed SARS-CoV-2 infection (COVID-19). www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-001023-14\/GB [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0635","unstructured":"ClinicalTrials.gov. NCT04408794. Long-term safety study of BHV-3500 (Zavegepant*) for the acute treatment of migraine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04408794. Published 2021 [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0640","unstructured":"Covis Pharma. Covis Pharma B.V. Initiates Phase 3 Clinical Trial of Alvesco (Ciclesonide) Inhaler for the Treatment of COVID-19. prnewswire. www.prnewswire.com\/news-releases\/covis-pharma-bv-initiates-phase-3-clinical-trial-of-alvesco-ciclesonide-inhaler-for-the-treatment-of-covid-19-301061105.html [accessed July 2, 2021]."},{"issue":"12","key":"10.1016\/j.drudis.2021.07.021_b0645","doi-asserted-by":"crossref","DOI":"10.2196\/23830","article-title":"Efficacy and safety of inhaled ciclesonide in treating patients with asymptomatic or mild COVID-19 in the RACCO Trial: protocol for a multicenter, open-label, randomized controlled trial","volume":"9","author":"Terada-Hirashima","year":"2020","journal-title":"JMIR Res Protocols"},{"key":"10.1016\/j.drudis.2021.07.021_b0650","unstructured":"Covis Pharma. Covis Pharma Group announces top-line safety and efficacy data from a phase 3 placebo-controlled COVID-19 study using inhaled corticosteroid (ciclesonide). www.globenewswire.com\/news-release\/2021\/04\/15\/2210630\/11011\/en\/COVIS-PHARMA-GROUP-Announces-Top-line-Safety-and-Efficacy-Data-from-a-Phase-3-Placebo-Controlled-COVID-19-Study-Using-Inhaled-Corticosteroid-ciclesonide.html [accessed July 2, 2021]."},{"issue":"31","key":"10.1016\/j.drudis.2021.07.021_b0655","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1016\/j.vaccine.2020.05.064","article-title":"Consensus summary report for CEPI\/BC March 12\u201313, 2020 meeting: assessment of risk of disease enhancement with COVID-19 vaccines","volume":"38","author":"Lambert","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.drudis.2021.07.021_b0660","unstructured":"CIOMS\/WHO Working Group on Vaccine Pharmacovigilance. Definition and application of terms for vaccine pharmacovigilance: report of CIOMS\/WHO Working Group on Vaccine Pharmacovigilance. Geneva; WHO; 2012."},{"issue":"1","key":"10.1016\/j.drudis.2021.07.021_b0665","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-020-0147-3","article-title":"Ebola virus disease","volume":"6","author":"Jacob","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.drudis.2021.07.021_b0670","unstructured":"WHO. Ebola vaccine candidates. www.who.int\/blueprint\/priority-diseases\/key-action\/ebola-vaccine-candidates\/en\/ [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0675","unstructured":"Aptar. Nasal vaccines. www.aptar.com\/products\/pharmaceutical\/nasal-vaccines\/ [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0680","unstructured":"Optinose. Exhalation delivery systems. www.optinose.com\/exhalation-delivery-systems\/technical-overview [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0685","unstructured":"BD. BD Accuspray\u2122 nasal spray system. https:\/\/drugdeliverysystems.bd.com\/products-and-services\/products\/prefillable-syringe-systems\/vaccine-syringes\/accuspray-nasal-spray-system [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0690","unstructured":"ICDRA. Vaccines. https:\/\/cdsco.gov.in\/opencms\/opencms\/en\/biologicals\/Vaccines\/index.html [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0695","unstructured":"FDA Nasal spray and inhalation solution, suspension, and spray drug products--chemistry, manufacturing, and controls documentation. www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/nasal-spray-and-inhalation-solution-suspension-and-spray-drug-products-chemistry-manufacturing-and [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0700","unstructured":"Our World in Data. Coronavirus (COVID-19) vaccinations - statistics and research. https:\/\/ourworldindata.org\/covid-vaccinations [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0705","unstructured":"Business Insider. A future COVID-19 vaccine could be squirted up the nose. The nasal spray could stop transmission, especially in kids. www.businessinsider.in\/science\/news\/a-future-covid-19-vaccine-could-be-squirted-up-the-nose-the-nasal-spray-could-stop-transmission-especially-in-kids-\/articleshow\/81355447.cms [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0710","unstructured":"Avalon GloboCare. Clinical trials aim to tackle COVID-19, with nasal spray vaccine and \u2018cytokine storm\u2019 blood filtering system. www.nature.com\/articles\/d43747-020-01139-4 [accessed July 2, 2021]."},{"key":"10.1016\/j.drudis.2021.07.021_b0715","unstructured":"The San Diego Union-Tribune. Future COVID-19 vaccines could come in a capsule or spray -. www.sandiegouniontribune.com\/news\/health\/story\/2021-04-19\/covid-19-vaccines-minus-the-needle-researchers-working-on-capsules-nasal-sprays [accessed July 2, 2021]."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644621003317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644621003317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:55:20Z","timestamp":1761224120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644621003317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":145,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S1359644621003317"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2021.07.021","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2021.07.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}